CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 194 filers reported holding CYMABAY THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 1.14 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $169,124 | +23.9% | 11,343 | -9.0% | 0.10% | +27.2% |
| Q2 2023 | $136,547 | -33.7% | 12,470 | -69.0% | 0.08% | +92.9% |
| Q3 2019 | $206,000 | -32.2% | 40,232 | -5.3% | 0.04% | -34.4% |
| Q2 2019 | $304,000 | -26.0% | 42,473 | +37.2% | 0.06% | -92.7% |
| Q1 2019 | $411,000 | +51.7% | 30,947 | -10.1% | 0.87% | +1800.0% |
| Q4 2018 | $271,000 | -32.2% | 34,437 | -4.7% | 0.05% | +12.2% |
| Q3 2018 | $400,000 | -51.9% | 36,120 | -41.7% | 0.04% | -94.4% |
| Q2 2018 | $831,000 | -31.4% | 61,951 | -33.6% | 0.74% | -30.1% |
| Q1 2018 | $1,212,000 | +210.0% | 93,317 | +119.6% | 1.05% | +114.3% |
| Q4 2017 | $391,000 | – | 42,485 | – | 0.49% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 1,629,464 | $14,208,926 | 10.61% |
| Lynx1 Capital Management LP | 1,369,927 | $11,945,763 | 9.96% |
| Versant Venture Management, LLC | 543,753 | $4,741,526 | 9.88% |
| Foresite Capital Management IV, LLC | 1,787,094 | $15,583,460 | 8.09% |
| Octagon Capital Advisors LP | 4,570,918 | $39,858,405 | 5.74% |
| ACUTA CAPITAL PARTNERS, LLC | 878,500 | $7,660,520 | 5.64% |
| TCG Crossover Management, LLC | 3,048,257 | $26,580,801 | 5.18% |
| Affinity Asset Advisors, LLC | 1,083,118 | $9,444,789 | 3.12% |
| Altium Capital Management LP | 620,000 | $5,406,400 | 3.00% |
| Bain Capital Life Sciences Investors, LLC | 2,500,000 | $21,800 | 2.72% |